The U.S. Food and Drug Administration (FDA) on Thursday approved Amgen Inc.’s (NASDAQ:AMGN) Uplizna (inebilizumab-cdon) as the first and only treatment for adult patients with Immunoglobulin ...
The prescribed dosage for Uplizna (inebilizumab-cdon) may vary depending on a person’s individual treatment plan. Other factors, including your specific diagnosis, body weight, and medical history, ...
With a label expansion for Uplizna pushing the drug into an untouched rare disease market, Amgen is getting its money’s worth out of another drug from its $27.8 billion Horizon Therapeutics buy.
The FDA’s approval of inebilizumab has heralded a new era for patients with IgG4-related disease, while novel agents moving ...
Horizon Therapeutics Public Limited Company HZNP announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) has rendered a positive opinion on, and has ...
NMOSD is a unifying term for neuromyelitis optica (NMO) and related syndromes. NMOSD is a rare, severe, relapsing, neuroinflammatory autoimmune disease that attacks the optic nerve, spinal cord and ...
The CD19-targeted rare disease medicine Uplizna was one of the crown jewels in Amgen’s $27.8 billion buyout of Horizon Therapeutics. Now, with a phase 3 triumph in progressive fibroinflammatory ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Uplizna doses are given via 90-minute intravenous infusions by a healthcare professional in a clinical setting. You will be monitored for at least one hour after the infusion is complete. Dosing ...
Uplizna (inebilizumab-cdon) is a prescription drug approved to treat certain autoimmune disorders. Uplizna comes as a solution for intravenous (IV) infusion into a vein. Specifically, Uplizna is used ...
Amgen has bagged a second indication for its B cell-depleting therapy Uplizna after the FDA cleared it for rare inflammatory disease IgG4-related disease (IgG4-RD). Acquired as part of its $27.8 ...
DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that its strategic partner Mitsubishi Tanabe Pharma Corporation (MTPC) has received manufacturing and marketing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results